Cell Therapeutics (CTIC -0.7%) says the Gynecologic Oncology Group has informed it that an independent Data Safety Monitoring Board has recommended the continuation of Phase 3 clinical trials of Opaxiotm, a therapy for ovarian cancer, with no changes following a planned interim survival analysis.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs